Selecta Biosciences Inc

NASDAQ:SELB   3:59:55 PM EDT
3.04
+0.12 (+4.11%)
Products, Regulatory

Selecta Biosciences Reported Top-Line Data From Phase 1 Clinical Trial Of ImmTOR Platform

Published: 11/08/2021 13:17 GMT
Selecta Biosciences Inc (SELB) - Selecta Biosciences Announces Top-line Data From Phase 1 Clinical Trial for Potential of Immtor Platform in Mitigating Formation of Neutralizing Antibodies Against Aav8 Vectors in Gene Therapies.
Selecta Biosciences - Aav8 Empty Capsids Elicited Peak Median Anti-aav8 Neutralizing Antibody (nab) Titers of 1:6875.
Selecta Biosciences - No Serious Adverse Events Were Reported.